Genentech starts study with Swiss antibody
Geneva – There's is life in Swiss biotechnology beyond big pharma. Genentech has launched a First-in-Human study with anti-IL-17, an antibody made by the Swiss biotechnology company NovImmune. The fully human monoclonal antibody, which may be suitable to treat inflammatory and autoimmune diseases, is designed to specifically and selectively bind to the human IL-17 family of cytokines NovImmune has developed its own technology to make monoclonal antibodies, or bioengineered molecules that mimic the action of the body’s own response to infections. Anti-IL-17 was licensed to Genentech in July 2010. The initiation of the Phase I clinical trial triggers a milestone payment from Genentech of an undisclosed amount. "This is the fifth NovImmune therapeutic antibody to enter clinical development", said Novimmune's CEO Jack Barbut. Two compounds are already in Phase II.